Connect with us

CureApp Announces Results from World’s First Randomized Control Study for Digital Therapeutic Smoking Cessation App

Published

on

Reading Time: 3 minutes

Results Confirm the Efficacy of CureApp’s Nicotine Dependence
Treatment Application

TOKYO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/ClinicalTrial?src=hash” target=”_blank”gt;#ClinicalTriallt;/agt;–Results from the world’s first randomized control study to examine
digital therapeutic smoking cessation programs were presented on May 20th
at the American Thoracic Society International Conference. The findings
demonstrate that CureApp’s nicotine dependence treatment app resulted in
an improvement in continuous abstinence rate (CAR) compared to a control
group over multiple time points.

Kohta Satake, M.D., M.B.A., M.P.H., Chief Executive Officer of CureApp,
Inc.
and a respiratory specialized physician says, “Healthcare
professionals are challenged to help patients fight against the
psychological nicotine addiction alone between clinical visits.
CureApp’s digital therapeutics approach is a breakthrough in bridging
the gap between clinical visits providing daily support to the patients.
We are striving for regulatory and reimbursement approval to deliver the
solution as soon as possible.”

The CureApp solution delivers information and educational material
through an app that is conveniently on the patient’s smartphone,
together with a Carbon Monoxide (CO) monitor for tracking their
progress, and a web interface for physicians. CureApp’s system is the
first such program to undergo the rigorous testing of Phase III clinical
trials. With this confirmation of its efficacy, CureApp’s goal is to use
this data to obtain regulatory approval and health insurance coverage in
Japan and to expand globally in multiple countries including the United
States.

Nicotine dependence

Nicotine dependence is a type of drug dependence; its intensity has been
reported to be comparable to that of heroin and cocaine*1.
Smoking is the Number 1 leading cause of preventable death in Japan*2
and the US*3.

The Clinical Trial

CureApp’s Phase III clinical trial in Japan was completed in December
2018, and the results were presented at the America Thoracic Society
International Conference, ATS 2019 by Dr. Hiroki Tateno, Division of
Pulmonary Medicine, Department of Medicine, Keio University, School of
Medicine.

The continuous abstinence rate (CAR)* at 9 to 24 weeks, the primary
endpoint to verify the efficacy of the CureApp Smoking Cessation, was
statistically significantly higher in the trial treatment group than the
control group, demonstrating that the CureApp Smoking Cessation
contributed to continuous smoking abstinence.

*Continuous abstinence rates at 9 to 24 weeks: Rates of patients who
continuously abstained from smoking at 9 to 24 weeks after the start of
smoking cessation treatment
.

The clinical trial was a multicenter, randomized, prospective, two-group
comparative study of the efficacy and safety of the CureApp Smoking
Cessation in combination with the standard smoking cessation treatment
program in patients with nicotine dependence who visited a smoking
cessation clinic. In this clinical trial, the CureApp Smoking Cessation
(smartphone application for patients, portable CO checker for patients,
and web-based application for physicians) or control device (the control
group application) was used for 24 weeks in addition to the standard
smoking cessation program.

Of the 584 patients who participated in this trial, 285 patients were
assigned to the treatment group using the application for nicotine
dependence treatment, 287 patients were assigned to the control group
using the control application. Total of 572 patient data was used for
analysis. The main evaluation item is “Continuous Abstinence Rate (CAR)
at Week 9-24”.

Efficacy

The CAR at 9 to 24 weeks, the primary endpoint, was 63.9% (182/285
subjects) in the trial treatment group and 50.5% (145/287) in the
control group. The CAR was higher by 13.4% in the trial treatment group,
showing a statistically significant difference (95% confidence interval,
1.239-2.424; P = 0.001), with an odds ratio of 1.73. The result
demonstrates that the CureApp Smoking Cessation contributed to
continuous smoking abstinence.

*1 Source: Kinen no Igaku (Medicine of Smoking Cessation), Japan
Medical Association
https://www.med.or.jp/forest/kinen/medical/
(Japanese)

*2 Source: Adult Mortality Attributable to Preventable Risk Factors for
Noncommunicable Diseases and Injuries in Japan in 2007, the Ministry of
Health, Labour and Welfare
https://www.mhlw.go.jp/topics/tobacco/houkoku/dl/120329_1.pdf
(Japanese)

*3 Source: Health Effects of Cigarette Smoking, CDC
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking/index.htm

About CureApp

CureApp, Inc., a MedTech venture company, engages in research and
development to create and market medical programs and devices for
disease treatment with advanced software technology and medical
evidence. Its pioneering work in digital therapeutics will bring new
solutions for a variety of conditions, including nicotine addiction,
diabetes, and hypertension amongst others.

Currently, CureApp is jointly developing a nicotine dependence treatment
solution with the Division of Pulmonary Medicine, Keio University,
School of Medicine (clinical trial completed), a non-alcoholic
steatohepatitis (NASH) treatment solution with the University of Tokyo
Hospital (clinical trial in progress), and a hypertension treatment
solution with Cardiovascular Medicine, Jichi Medical University
(clinical trial in progress).

By leveraging the knowledge and findings accumulated in the development
of these treatment applications for medical institutions, CureApp
provides mobile health programs for private corporations and health
insurance associations, including the “ascure Smoking Cessation Program”
and “ascure STEPS Lifestyle Habit Improvement Program.” CureApp plans to
expand these and other digital therapeutic solutions from Japan to the
global market. For more information visit, https://cureapp.co.jp/en/.

Contacts

For US media
Joy Scott, CEO, Scott
Public Relations
E-mail: Joy@scottpublicrelations.com
Phone:
818.610.0270

For media from other countries
Nanako
Daime, Public Relations Manager, CureApp, Inc.
E-mail: nanako.daime@cureapp.jp

Cannabis

Strainprint™ Technologies Welcomes Organic Medical Cannabis Producer to Growing List of Subscribers

Published

on

Reading Time: 2 minutes

 

Strainprint™ Technologies Ltd, the leader in cannabis data and analytics is pleased to expand their nation-wide coverage with the addition of Stewart Farms.

Stewart Farms is a late-stage applicant headquartered in Alberta that is building a 100,000 sq. ft. vertical aquaponics farm in Saint StephensNew Brunswick. They will be utilizing automation, vertical farming, and land-based aquaculture to produce medical grade organic cannabis for both recreational and medical markets in Canada. All of their products will be free of herbicides, pesticides and synthetic nutrients. At full capacity, they will reach more than 10,000 kgs per year of organically farmed cannabis and more than 200,000 kgs of organic tilapia.

Stewart Farms’ long term vision is to deliver tools and products to support  future customers and patients during their health and wellness journeys. “Through our partnership with Strainprint we gain direct access to their incomparable data and analytics tools. This will aid us in educating a wider audience on the medical benefits and best practices of cannabis-based medicine,” said Tanner Stewart, Co-founder & CEO of Stewart Farms. “We know our customers are looking to consume more than dried cannabis. We know Canadians of all legal ages are trying to sort through their personal engagement with cannabis as a medicine. What we want to know, on an ongoing basis, is what is and is not working for people. Strainprint’s patient-led data services will give us the insight needed to create custom products and further understand the benefits of our existing products. Finally, our goal is to partner with companies and teams that truly have people’s best interest at heart. Caring about a patient’s success is what makes up the core of the Strainprint team. We couldn’t be happier to move forward with them at our side.”

Stewart Farms will access the Strainprint Analytics web platform, the most sophisticated cannabis analytics platform available to improve product development. Strainprint Analytics is built on top of the largest and most granular scientific data set of its kind in the world, with more than 1.3 million anonymized, patient reported medical cannabis outcomes and more than 65 million data points on strain efficacy.

“We’re thrilled to provide our real-time, crowd sourced data to an environmentally conscious company that uses innovative, cutting edge farming technology to produce top-tier medical cannabis,” said Strainprint CEO, Andrew Muroff. “Our organizations are equally committed to improving lives using cannabis therapy, and our shared core motivation is to provide guidance and support to help cannabis patients achieve their health goals.”

 

SOURCE Strainprint Technologies Ltd.

Continue Reading

Cannabis

Field Trip Ventures Inc. Retains KCSA Strategic Communications as Public Relations Counsel

Published

on

Reading Time: 1 minute

 

Greenery Map, the world’s first and only cannabis search engine to allow users to search for cannabis products based on their desired mood, medicinal use, and method of consumption, is now offering users – both businesses and consumers – the opportunity to register and connect to the app in an entirely mobile way. Previously, businesses were required to access GreeneryMap.com from a desktop in order to manage accounts and connect to the inventory API system, but that road block has been removed, allowing for an entirely mobile experience through the Greenery Map app.

App users turn to Greenery Map to help them decide on the strain of Cannabis and product that is right for them depending on their desired mood or medicinal effect. Following the matching, consumers are given a detailed history and description of the strain so that they can make educated purchases, cutting down on time that budtenders need to spend with patrons and speeding up the purchase process. Consumers can then see all of the ways to purchase said product, including the nearby dispensaries that have it in stock, online options, and even delivery options through the app. Greenery Map fully integrates with a dispensary’s inventory API system to update in real-time and give consumers real-time information on dispensary stock for the item they are looking for. The Greenery Map system also provides cannabis businesses in both the B2B and B2C sectors a private database to share and sell information and products. For Cannabis businesses, Greenery Map also offers the opportunity to open bank and merchant accounts through their partnership with PayHouse Consulting Group.

 

SOURCE Greenery Map

Continue Reading

Cannabis

WeBank, IBM and Other Organizations Jointly Held the 1st International Workshop on Federated Machine Learning in conjunction with IJCAI 2019

Published

on

Reading Time: 4 minutes

 

Once a concept, AI is now ushering in a key stage of application. What’s the solution to the data silos among businesses? Given the enhanced regulation on data at home and abroad, what’s the solution to data privacy and security concerns? What’s the status quo of Federated Machine Learning and how to establish an ecosystem for FML in the future?

WeBank, IBM and other organizations jointly held the 1st International Workshop on Federated Machine Learning for User Privacy and Data Confidentiality (FML’19) in conjunction with the 28th International Joint Conference on Artificial Intelligence (IJCAI-19) on Aug. 12, 2019, to further discussion on these issues.

President of IJCAI, Chair of FML Steering Committee, Chief AI Officer of WeBank Professor Qiang Yang delivered opening remarks at the workshop. Dr. Shahrokh Daijavad from IBM and Dr. Jakub Konečný from Google presented keynote addresses. In the panel discussion, top scholars from WeBank, Bar-Ilan University, IBM, Squirrel AI, Google, Huawei, Clustar, Sinovation Ventures and many other renowned enterprises and universities shared and discussed their findings and experience in FML as an emerging AI technology.

This workshop received 40 papers, of which 12 were presented during the workshop, 19 presented via poster. Awards include Best Theory Paper Award, Best Application Paper Award, Best Student Paper Award, Best Presentation Award. Selected high quality papers will be invited for publication in a special issue in the IEEE Intelligent Systems journal. All these attracted numerous scholars to engage in discussions and join efforts for building the FML ecosystem.

Experts from IBM and Google Share Groundbreaking Findings with a Focus on the Theory and Application of FML

Privacy and security are becoming a key concern in our digital age. On 25th May last year, the implementation of General Data Protection Regulation (GDPR) by the EU, the toughest Act on data privacy protection, stressed that user data collection must be open and transparent. A series of laws and regulations from China and overseas also pose new challenges to the traditional way of handling data and model for cooperation. Seeking ways for AI to adapt to this new reality became top priority, a demand that led to this workshop on FML.

A wealth of solutions and breakthroughs were shared by Dr. Shahrokh Daijavad from IBM and Dr. Jakub Konečný from Google in their speech on FML.

Besides how FML can help tackle challenges in the business world, Dr. Shahrokh Daijavad also shared the concept of Fusion AI, which means to train models on widely distributed data sets, but fuse them to produce one equivalent to what centralized training would yield. “Unlike traditional machine learning, in Fusion AI, model parameters are shared and data is not transferred, which makes Fusion AI model better than models that moving data centrally.” Given the widely distributed data, the development of Fusion AI and FML became ever important and imminent.

“FML enables machine learning engineers and data scientists to work productively with decentralized data with privacy by default,” said Dr. Jakub Konečný from Google. He also shared with us how FML works and its use cases at Google. In the case of Gboard, as on-device data is privacy sensitive or large or is more relevant than server-side proxy data, and labels can be inferred naturally via user interaction, the application of Federated RNN compared to prior n-gram model can increase the accuracy of next-word prediction by 24%, and the click rate of prediction strip by 10%.

Major Figure Panelists Discuss the Way Ahead for FML

The moderator of the panel discussion, AI Principal Scientist of WeBank Dr. Lixin Fan joined panelists including Professor Benny Pinkas from Bar-Ilan University, Dr. Shahrokh Daijavad of IBM Academy of Technology, Chief Architect of Squirrel AI Dr. Richard Tong, Research Scientist of Google Dr. Jakub Konečný, Dr. Baofeng Zhang from CTO Office of CBG Software in Huawei, Executive VP of Clustar Dr. Junxue Zhang, VP of AI Institute in Sinovation Ventures Dr. Ji Feng and other experts in a host of in-depth exchanges with attendees, to shed light on the way ahead for FML.

Experts shared thoughts in the panel discussion on questions including but not limited to: How to meet the security and compliance requirements? Is there a way to extend the value of data while observing user privacy and data security? Given the classic trade-off between data regulation and development of AI, how to achieve the long-term goal of establishing a stable and win-win business ecosystem?

List of Award-Winners

Best Theory Paper Award, Best Application Paper Award, Best Student Paper Award and Best Presentation Award selected by all attendees were announced at the closing of the workshop.

Best Theory Paper Award: 
Preserving User Privacy for Machine Learning: Local Differential Privacy or Federated Machine Learning? By Huadi Zheng, Haibo Hu & Ziyang Han;

Best Application Paper Award: 
FedHealth: A Federated Transfer Learning Framework for Wearable Healthcare. By Yiqiang ChenJindong WangChaohui YuWen Gao & Xin Qin;

Best Student Paper Award: 
Quantifying the Performance of Federated Transfer Learning. By Qinghe JingWeiyan Wang, Junxue Zhang, Han Tian & Kai Chen;

Best Presentation Award: 
Federated Generative Privacy. By Aleksei Triastcyn and Boi Faltings.

President of IJCAI, Chief AI Officer of WeBank Professor Qiang Yang, Chief Architect of Squirrel AI Dr. Richard TongandVP of AI Institute in Sinovation Ventures Dr. Ji Feng presented the awards.

“The mission of this International Federated Machine Learning Workshop is to facilitate further understanding in the academia, business community as well as legal and regulatory institutions by promoting the establishment of FML ecosystem in the hope that more businesses will join and build a platform for students aspired to work in FML to find research teams that suit them,” said Professor Qiang Yang.

Held Aug. 10-16, 2019 in Macao, China, IJCAI-19 is one of the leading International Academic Conference on AI, attracting over 3000 AI research personnel and experts. The 1st International Workshop on Federated Machine Learning (FML’19) was a highlight for experts joining this event. Visionaries in the academia and industrial sector expressed the willingness to be part of the effort for academic research, application of FML in the future, and the development and boom of AI ecosystem.

Continue Reading

Trending Online

Grassnews is a news publishing website which digests / hand picks the latest news about the cannabis industry, and serves them to you daily.

Contact us: pressroom@grassnews.net

© Grassnews.net 2019 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania